VeraMorph

Building on 20 years of drug delivery expertise, Veramed focusses on developing non-prescription drugs, medical devices and food-supplements. Innovative, patent protected, effective and consumer friendly solutions for health problems related to common cold, nasal congestion, vitamin deficiencies, motion sickness and sleep.

We are committed to developing licensed medicinal products that meet the specific needs of our patients. We are passionate in our belief that all patients deserve access to the highest quality medicinal products. We are always on the lookout for differentiated medicines and late-stage opportunities that could fit with our growing portfolio and can improve the standard of care for more patients around the world. The company was founded in 1997 by Dr Graham March, a pharmacist with substantial experience of the formulation of medicines gained whilst working at major pharmaceutical companies and within the UK’s National Health Service. The team of formulation experts at Veriton Pharma has since developed more than 60 “specials” for a targeted range of therapeutic areas. The company has grown rapidly, supplying products to more than 25 countries. In May 2020 Veriton Pharma were acquired by SERB Pharmaceuticals, a leading European specialty pharmaceutical group focused on prescription medicines that address rare and life-threatening diseases. SERB’s focus on critical care and answering unmet needs is closely aligned with Veriton’s history and approach, and as part of an integrated group they can take their growth to the next level.

Our mission is to change the standard of care for patients with immunologic diseases. We are developing multiple novel biologic molecules toward this end. Fordyce brings more than 15 years’ experience leading teams in drug discovery, development, clinical translation, and commercialization of new treatments. Brenner brings more than 25 years of experience as a respected nephrologist and a successful biotechnology executive. Lauren Frenz, MBA, has 15 years of experience in the biotech industry. Turner has nearly 30 years of drug development and commercialization experience, leading multiple organizations through all phases of product development including the development of the final commercial drug process, method, facility, and process validations, all phases of clinical programs, numerous drug application filings and the transition and establishment of several critical commercialization processes. Prior to joining Vera, Turner served as the Chief Regulatory and Technical Operations Officer at Sierra Oncology, Inc. Capers worked at the industry-leading consulting firms, The Zitter Group (acquired by Managed Markets Insight & Technology) and Defined Health (now part of Lumanity), providing managed markets and business development strategy services to life sciences clients.

MedCara, LLC is a formulation and licensing biotechnology company. MedCara Pharmaceuticals seeks to discover, develop, and commercialize pharmaceutical formulations independently and with clinical and industry partners. MedCara's proprietary, systematic, compounding-based platform, is designed to accelerate the discovery of new drug uses and to expand intellectual property coverage of drug candidate compounds and classes of related compounds. MedCara retains royalty rights to downstream revenue generated by the compounding pharmacies. MedCara's drug design approach combines diverse formulation technology disciplines and an integrated clinical organizational philosophy to increase the speed and success rate of new drug applications and development. MedCara's flagship product is WartPEEL®, a topical treatment that eliminates planter and common warts. MedCara’s focus on drug development is to collaborate with compounding pharmacies, develop over-the-counter medications, supplements, and homeopathic products; and to collaborate with strong commercial partners for research and manufacturing to avoid high costs. Within a dynamic core framework of pharmacology, pharmaceutics, and biophysics, MedCara Pharmaceuticals and its prescriber relationships have developed a variety of proprietary drug formulations.

We are one of India’s leading healthcare enterprise with relevance in the fields of Narcotics (analgesics & anaesthetics segment) and Psychotropics products. We are technologically driven and socially conscious that helps, to ensure quality, security and control in distributed manufacturing and delivery environments. Globally we are recognized & approved by SFDA-Saudi Arabia, FMHACA-Ethiopia, TFDA-Tanzania, PPB-Kenya, NDA-Uganda, PMBP-Malawi, GMP-Ivory Coast and by many more countries. Our vision at Verve is to be a Global Pharmaceutical Company, serving health in different ways to suit and fulfill the requirements of every modern day consumer. Our strong portfolio of businesses, geographies and products provide us the strategic benefits of integration that allow us to perform best in an increasingly competitive market. Our manufacturing plant Verve Human Care Laboratories facilities are state-of-the-art and are certified by ISO 9001:2015. And be recognized worldwide as a trusted, most Admired for its Affordability, Quality and Accessibility of Products. Access to patients.Commitment towards protecting environment.High quality products for pain management.

Neomorph is a venture backed biotechnology company solving critical problems in human health through the discovery and development of innovative new medicines against ‘undruggable targets’. We are committed to leadership in advancing the science and technology of molecular glue drug discovery, while prosecuting a pipeline of projects through clinical development. Neomorph is headquartered in San Diego, California, and has a key collaboration with the Center for Protein Degradation at the Dana Farber Cancer Institute. Deerfield Management Company established Neomorph earlier this year with scientific founders Phil Chamberlain, DPhil, Eric Fischer, PhD, Benjamin Ebert, MD, PhD, and Scott Armstrong, MD, PhD. Of particular note, Neomorph’s founders are responsible for several fundamental scientific developments in the “molecular glue” field. Neomorph plans to build on the collective pivotal research findings of the team to advance the technology of targeted protein degradation and solve critical problems in human health. We believe we are in an excellent position to take our technology to the next level with the ultimate goal of delivering transformative treatments to patients in need.”. Neomorph is in an exceptional position and couldn’t have a more seasoned and knowledgeable team in place to interrogate and advance drug targets.